Долгая жизнь с муковисцидозом. Коллектив авторов
1162-3.
157
Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182: 298–306.
158
Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182: 298–306.
159
Flume PA, Strange C, Ye X, etal. Pneumothorax in cystic fibrosis. Chest 2005; 128:720-8.
160
Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182: 298–306.
161
Moen CA, Burrell A, Dunning J. Does tranexamic acid stop haemoptysis? Interact Cardiovasc Thorac Surg 2013; 17: 991-4.
162
Moua J, Nussbaum E, Liao E, et al. Beta-blocker management of refractory hemoptysis in cystic fibrosis: a novel treatment approach. Ther Adv Respir Dis 2013;7:217-23.
163
Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest 2005; 128: 729-38.
164
Barben JU, Ditchfield M, Carlin JB, et al. Major haemoptysis in children with cystic fibrosis: a 20-year retrospective study. J Cyst Fibros 2003; 2: 105-11.
165
Giron Moreno RM, Caballero R Friera A. Multidetector computed tomography angiography for pre-embolization assessment in cystic fibrosis patients with massive haemoptysis. Respir Med 2014; 108:816-7.
166
Cornalba GP, Vella A, Barbosa F, et al. [Bronchial and nonbronchial systemic artery embolization in managing haemoptysis: 31 years of experience], Radiol Med 2013; 118: 1171-83.
167
Pestana Knight EM, Novelli PM, Joshi SM. Cerebral and systemic infarcts after bronchial artery embolization. Pediatr Neurol 2011;45:324-7.
168
Daliri A, Probst NH,Jobst В et al. Bronchial artery embolization in patients with hemoptysis including follow-up. Acta Radiol 2011; 52: 143-7.
169
Lau EM,Yozghatlian V, Kosky C, et al. Recombinant activated factor VII for massive hemoptysis in patients with cystic fibrosis. Chest 2009; 136:277-81.
170
Rolla M, D'Andrilli A, Rendina EA, et al. Cystic fibrosis and the thoracic surgeon. Eur J Cardiothorac Surg 2011; 39: 716-25.
171
Jones A, Bilton D, Evans TW, et al. Predictors of outcome in patients with cystic fibrosis requiring endotracheal intubation. Respirology 2013; 18: 630-6.
172
Middleton PG, Chen SC, Meyer W. Fungal infections and treatment in cystic fibrosis. Curr Opin Pulm Med 2013; 19: 670-5.
173
Agarwal R, Chakrabarti A, Shah A, et al. ABPA complicating asthma ISHAM working group. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43: 850-73.
174
Geller DE, Kaplowitz H, Light MJ, et al. Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Chest 1999; 116: 639-46.
175
Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Eur Respir J 2000; 16: 464-71.
176
Agarwal R, Chakrabarti A, Shah A, et al. ABPA complicating asthma ISHAM working group. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43: 850-73.
177
Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppfl3):S225-64.
178
Agarwal R, Khan A, GargM,etal. Chest radiographic and computed tomographic manifestations in allergic bronchopulmonary aspergillosis. World J Radiol 2012; 4: 141-50.
179
Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppfl3):S225-64.
180
Hemmann S, Nikolaizik WH, Schoni MH, etal. Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. Eur J Immunol 1998; 28: 1155-60.
181
Nikolaizik WH,Weichel M, Blaser K, et al. Intracutaneous tests with recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and Aspergillus allergy. Am J Respir Crit Care Med 2002; 165: 916-21.
182
Hemmann S, Nikolaizik WH, Schoni MH, etal. Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. Eur J Immunol 1998; 28: 1155-60.
183
Fricker-Hidalgo H, Coltey B, Llerena C, et al. Recombinant allergens combined with biological markers in the diagnosis of allergic bronchopulmonary aspergillosis in cystic fibrosis patients. Clin Vaccine Immunol 2010; 17: 1330-6.
184
Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppfl3):S225-64.
185
Thomson JM, Wesley A, Byrnes CA, et al. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41:164-70.
186
Thomson JM, Wesley A, Byrnes CA, et al. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41:164-70.
187
Thomas MF, Life-threatening allergic bronchopulmonary aspergillosis treated with methylprednisolone and anti-lgE monoclonal antibody. J R Soc Med 2009; 102(Suppl 1): 49–53.
188
Thomas MF, Life-threatening allergic bronchopulmonary aspergillosis treated with methylprednisolone and anti-lgE monoclonal